Promoted Content Promoted Content


Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): RZL 012

            Therapeutic Area: Rare Diseases and Disorders Product Name: RZL 012

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Fosun Pharmaceutical

            Deal Size: $74.0 million Upfront Cash: $27.0 million

            Deal Type: Licensing Agreement September 17, 2020


            RZL-012 is an injectable drug product indicated for aesthetic treatment of adults having moderate to significant submental fullness. Under the terms of the agreement, Raziel Therapeutics will receive potential payments between now and marketing approval in the Territory.